A5003932609- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Pleural and Pulmonary Diseases
- Tracheal and airway disorders
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging and Pathology Studies
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- Myasthenia Gravis and Thymoma
- Neuroendocrine Tumor Research Advances
- RNA modifications and cancer
- Metastasis and carcinoma case studies
- Cardiac tumors and thrombi
- Occupational and environmental lung diseases
- Salivary Gland Tumors Diagnosis and Treatment
- Trauma Management and Diagnosis
- Cancer-related molecular mechanisms research
- Gastric Cancer Management and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Congenital Diaphragmatic Hernia Studies
- Esophageal Cancer Research and Treatment
- Advanced Radiotherapy Techniques
- Neuroblastoma Research and Treatments
- Medical Imaging Techniques and Applications
- Cancer Genomics and Diagnostics
University of Milan
2016-2025
European Institute of Oncology
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2007-2025
Ripamonti
2013-2024
Azienda Sanitaria Unità Locale di Reggio Emilia
2015-2024
Philipps University of Marburg
2023
Peking University
2022
Zhejiang Cancer Hospital
2022
University of Chinese Academy of Sciences
2022
Peking University Cancer Hospital
2022
Notch signaling regulates cell specification and homeostasis of stem compartments, it is counteracted by the fate determinant Numb. Both Numb have been implicated in human tumors. Here, we show that altered approximately one third non–small-cell lung carcinomas (NSCLCs), which are leading cause cancer-related deaths: ≈30% NSCLCs, loss expression leads to increased activity, while a smaller fraction cases (around 10%), gain-of-function mutations NOTCH-1 gene present. Activation correlates...
This study aimed to determine whether three preoperative cycles of gemcitabine plus cisplatin followed by radical surgery provides a reduction in the risk progression compared with alone patients stages IB IIIA non-small-cell lung cancer (NSCLC).Patients chemotherapy-naive NSCLC (stages IB, II, or IIIA) were randomly assigned receive either 1,250 mg/m(2) days 1 and 8 every 3 weeks 75 day surgery, alone. Randomization was stratified center disease stage (IB/IIA v IIB/IIIA). The primary end...
Lung cancer is the leading cause of death worldwide. Low-dose computed tomography screening (LDCT) was recently shown to anticipate time diagnosis, thus reducing lung mortality. However, concerns persist about feasibility and costs large-scale LDCT programs. Such may be addressed by clearly defining target “high-risk” population that needs screened LDCT. We identified a serum microRNA signature (the miR-Test) could identify optimal population. Here, we performed validation study miR-Test in...
<b>Objective</b> To estimate the cumulative radiation exposure and lifetime attributable risk of cancer incidence associated with lung screening using annual low dose computed tomography (CT). <b>Design</b> Secondary analysis data from a trial risk-benefit analysis. <b>Setting</b> 10 year, non-randomised, single centre, CT, (COSMOS study) which took place in Milan, Italy 2004-15 (enrolment 2004-05). Secondary 2015-16. <b>Participants</b> High asymptomatic smokers aged 50...
Lung neuroendocrine tumors are catalogued in four categories by the World Health Organization (WHO 2004) classification. Its reproducibility and prognostic efficacy was disputed. The WHO 2010 classification of digestive neoplasms is based on Ki67 proliferation assessment proved prognostically effective. This study aims at comparing these two classifications defining a grading system for lung tumors. included 399 patients who underwent surgery with least 1 year follow-up between 1989 2011....
IntroductionThe International Registry of Lung Metastases defined a new staging system based on identified prognostic factors for long-term survival after metastasectomy. The aim our study was to confirm the validity classification in patients who underwent curative lung metastasectomy single center.MethodsWe retrospectively reviewed 575 708 metastasectomies from January 1998 October 2008. Complete pulmonary resections were performed 490 cases (85%). Three hundred seventy-two developed...
Background: Lung cancer screening may detect that will never become symptomatic (overdiagnosis), leading to overtreatment. Changes in size on sequential low-dose computed tomography (LDCT) screening, expressed as volume-doubling time (VDT), help distinguish aggressive from cases are unlikely symptomatic. Objective: To assess VDT for screening-detected lung an indicator of overdiagnosis. Design: Retrospective estimation the detected a prospective LDCT cohort. Setting: Nonrandomized,...
Exhaled breath contains hundreds of volatile organic compounds (VOCs). Several independent researchers point out that the lung cancer patients shows a characteristic VOC-profile which can be considered as signature and, thus, used for diagnosis. In this regard, analysis exhaled with gas sensor arrays is potential non-invasive, relatively low-cost and easy technique early detection cancer. This clinical study evaluated array response identification patients.
Screening with low-dose helical computed tomography (CT) has been shown to significantly reduce lung cancer mortality but the optimal target population and time interval subsequent screening are yet be defined. We developed two models stratify individual smokers according risk of developing cancer. first used number cancers detected at baseline CT in 5,203 asymptomatic participants COSMOS trial recalibrate Bach model, which we propose using select for screening. Next, incorporated nodule...
Abstract Purpose: New prognostic markers to guide treatment decisions in early stage non–small cell lung cancer are necessary improve patient outcomes. In this report, we assess the utility of a predefined mRNA expression signature cell-cycle progression genes (CCP score) define 5-year risk cancer–related death patients with adenocarcinoma. Experimental Design: A CCP score was calculated from levels 31 proliferation I and II tumor samples two public microarray datasets [Director's Consortium...